COVID-19

Two analyses found antiviral drugs like Paxlovid do not elevate the risk for COVID-19 rebound, contrary to previous research.

Data from transcatheter aortic valve replacement centers across 61 countries show TAVR volume fell precipitously during the first and second waves of the COVID-19 pandemic but rebounded to pre-pandemic volume during the third wave.

Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.

There was a downward trend for asthma attacks and ED visits among Black adults and children relative to white patients during the COVID-19 pandemic, according to a letter published in Annals of Internal Medicine.

In patients with immune-mediated inflammatory diseases, a 2-week pause of methotrexate after receiving a COVID-19 vaccine booster yielded a sustained, significantly increased antibody response, without serious flares, according to a study.

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs.

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies.

Healio Pulmonology has compiled the top news on COVID-19 posted in 2023.